Show simple item record

dc.contributor.authorSherlock, Mark
dc.contributor.authorAyuk, John
dc.contributor.authorTomlinson, Jeremy W
dc.contributor.authorToogood, Andrew A
dc.contributor.authorAragon-Alonso, Aurora
dc.contributor.authorSheppard, Michael C
dc.contributor.authorBates, Andrew S
dc.contributor.authorStewart, Paul M
dc.date.accessioned2012-11-30T10:41:16Z
dc.date.available2012-11-30T10:41:16Z
dc.date.issued2010-06
dc.identifier.citationMortality in patients with pituitary disease. 2010, 31 (3):301-42 Endocr. Rev.en_GB
dc.identifier.issn1945-7189
dc.identifier.pmid20086217
dc.identifier.doi10.1210/er.2009-0033
dc.identifier.urihttp://hdl.handle.net/10147/254077
dc.description.abstractPituitary disease is associated with increased mortality predominantly due to vascular disease. Control of cortisol secretion and GH hypersecretion (and cardiovascular risk factor reduction) is key in the reduction of mortality in patients with Cushing's disease and acromegaly, retrospectively. For patients with acromegaly, the role of IGF-I is less clear-cut. Confounding pituitary hormone deficiencies such as gonadotropins and particularly ACTH deficiency (with higher doses of hydrocortisone replacement) may have a detrimental effect on outcome in patients with pituitary disease. Pituitary radiotherapy is a further factor that has been associated with increased mortality (particularly cerebrovascular). Although standardized mortality ratios in pituitary disease are falling due to improved treatment, mortality for many conditions are still elevated above that of the general population, and therefore further measures are needed. Craniopharyngioma patients have a particularly increased risk of mortality as a result of the tumor itself and treatment to control tumor growth; this is a key area for future research in order to optimize the outcome for these patients.
dc.language.isoenen
dc.publisherEndocrine reviewsen_GB
dc.rightsArchived with thanks to Endocrine reviewsen_GB
dc.subject.meshAcromegaly
dc.subject.meshCohort Studies
dc.subject.meshCraniopharyngioma
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshHypopituitarism
dc.subject.meshMale
dc.subject.meshPituitary ACTH Hypersecretion
dc.subject.meshPituitary Diseases
dc.titleMortality in patients with pituitary disease.en_GB
dc.typeArticleen
dc.contributor.departmentCentre for Endocrinology, Diabetes, and Metabolism, School of Clinical and Experimental Medicine, College of Medical and Dental Sciences, University of Birmingham, Birmingham B15 2TH, United Kingdom.en_GB
dc.identifier.journalEndocrine reviewsen_GB
dc.description.provinceLeinsteren
html.description.abstractPituitary disease is associated with increased mortality predominantly due to vascular disease. Control of cortisol secretion and GH hypersecretion (and cardiovascular risk factor reduction) is key in the reduction of mortality in patients with Cushing's disease and acromegaly, retrospectively. For patients with acromegaly, the role of IGF-I is less clear-cut. Confounding pituitary hormone deficiencies such as gonadotropins and particularly ACTH deficiency (with higher doses of hydrocortisone replacement) may have a detrimental effect on outcome in patients with pituitary disease. Pituitary radiotherapy is a further factor that has been associated with increased mortality (particularly cerebrovascular). Although standardized mortality ratios in pituitary disease are falling due to improved treatment, mortality for many conditions are still elevated above that of the general population, and therefore further measures are needed. Craniopharyngioma patients have a particularly increased risk of mortality as a result of the tumor itself and treatment to control tumor growth; this is a key area for future research in order to optimize the outcome for these patients.


This item appears in the following Collection(s)

Show simple item record